J3247: Permanent J-code for the intravenous (IV) formulation of COSENTYX® (secukinumab)*

Effective July 1, 2024, for all sites of care

J3247:
Permanent J-code for the intravenous (IV) formulation of COSENTYX® (secukinumab)*

Effective July 1, 2024, for all sites of care

*If COSENTYX is administered on or after July 1, 2024, the permanent J-code replaces the miscellaneous J-code, J3590.

It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient. Novartis cannot guarantee insurance coverage or reimbursement.

Reference: CMS, HCPCS Quarterly Update, April 2024.

IV Dosing Information

The FIRST and ONLY IL-17A antagonist available in IV form
for adult patients with active PsA, AS, or nr-axSpA1-6

The FIRST and ONLY IL-17A antagonist available in IV form for adult patients with active PsA, AS, or nr-axSpA1-6

IV Dosing

Information

The FIRST and ONLY IL-17A antagonist available in IV form for adult patients with active PsA, AS, or nr-axSpA1-6